6533b823fe1ef96bd127f3dd
RESEARCH PRODUCT
SAFETY AND CLINICAL ACTIVITY OF TEMSIROLIMUS IN COMBINATION WITH RITUXIMAB AND DHAP IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA-REPORT OF THE PROSPECTIVE, MULTICENTER PHASE II STORM TRIAL
Reinhard MarksMathias Witzens-harigE. HönigUlrich KellerAndreas ViardotChristian BuskeMartin DreylingJ. AttaP. LaroseeGeorg Hesssubject
0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryHematologyGeneral MedicineTemsirolimus03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineDHAPmedicineRefractory Diffuse Large B-Cell LymphomaIn patientRituximabbusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2017-06-01 | Hematological Oncology |